Thermo Fisher Scientific has completed the acquisition of US-based cellular and genetic analysis products provider Affymetrix, for around $1.3bn.

As part of the deal, Thermo Fisher has paid $14.00 per share to the stakeholders of Affymetrix.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Earlier this month, Origin Technologies made an offer of around $1.5bn to buy Affymetrix, topping a $1.3bn bid from Thermo Fisher Scientific made this January.

“This transaction creates significant value for our stockholders and will provide important benefits to our customers and employees.”

Thermo Fisher Scientific president and CEO Marc Casper said: "With Affymetrix, we now have an expanded antibody portfolio to strengthen our leadership in biosciences, as well as new genetic analysis capabilities to better serve clinical and applied markets.

"Our combined capabilities will benefit our customers, employees and shareholders, and we are excited to move forward as one organisation positioned for growth."

Based in Santa Clara, California, Affymetrix provides products to the customers in various sectors, including life sciences and translational research, molecular diagnostics, reproductive health and agricultural biotechnology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Affymetrix president and CEO Frank Witney said: "This transaction creates significant value for our stockholders and will provide important benefits to our customers and employees."

Affymetrix also offers a range of antibodies, multiplex RNA, and protein and single-cell assays that serve cytometry market segment, as well as single-cell biology, immunotherapy and infectious disease research.

The company operates manufacturing facilities in Cleveland, San Diego, US, as well as Vienna, Austria and Singapore.